This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stackievicz, R. Articles by Cohen, I. Search for Related Content PubMed PubMed Citation Articles by Stackievicz, R. Articles by Cohen, I.

Tamoxifen Modulates Apoptotic Pathways in Primary Endometrial Cell Cultures

Oncogenetics Laboratory [R. S., L. D., S.Y.], Hematology Laboratory [J. R.], and Department of Obstetrics and Gynecology [Y. B., S. Y., I. C.], Sapir Medical Center, Meir Hospital, Kfar Sava 44281 and Sackler School of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel

	ABSTRACT

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Clinical data indicate that tamoxifen (TAM) therapy may cause an increased risk of endometrial pathology in postmenopausal but not in premenopausal women. Molecular mechanisms of the uterotrophic activity of TAM have not been clearly established nor its relevance to apoptosis in endometrial cells. The present study was implemented to evaluate the apoptotic effect of TAM on primary endometrial cell cultures in the presence or absence of steroid hormones (SHs). A total of 14 primary endometrial cell cultures were established and maintained both with and without SHs. Cell cultures were treated for 24 h with either 20 µM TAM or 10 nM estradiol. Apoptotic cells presented in a pre-G₁ peak and the expression of bcl-2 were studied using flow cytometry. All endometrial cell cultures maintained in a SH-containing environment, except one, responded to TAM by a significant increase (P = 0.03) in the pre-G₁ cell fraction, indicating a proapoptotic effect. A significant (P = 0.03) reduction in the pre-G₁ peak equivalent to an antiapoptotic response was observed in 6 of 13 cell cultures maintained in a SH-deficient environment. In 4 of 10 cell cultures evaluated in both media, the pre-G₁ population was medium dependent. In 8 of 10 cultures evaluated for Bcl2 levels, no trend was found in either media, but a dependency on SH content was observed. Comparison between effects of TAM and estradiol demonstrated identical trends, regardless of the menstrual phase or SH content in cell environments. These results suggest that TAM acts as an estrogen agonist on endometrial tissue in both environments. We conclude that TAM modulates apoptotic pathways in primary endometrial cell cultures. The SH content in the cell environment influences the apoptotic effect of TAM and determines the propensity for a cell to undergo apoptosis or, on the contrary, to resist apoptotic death in response to TAM treatment. This is in concordance with the observed clinical risk of endometrial pathologies in postmenopausal versus premenopausal women.

	INTRODUCTION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
TAM² is a nonsteroidal compound that binds to ERs and elicits estrogen agonist or antagonist responses, depending on the target tissue (1) . It is the most widely prescribed antineoplastic hormonal treatment agent today. Its effectiveness appears to be greatest in postmenopausal breast cancer patients with positive ER, but it is also effective in premenopausal patients (2) . TAM is also currently being evaluated as a preventive agent for healthy women with increased risk for breast cancer (3) .

There is sufficient clinical data to suggest that postmenopausal TAM therapy may cause an increased risk for the development of benign and malignant endometrial pathologies (4) . Although in premenopausal women there is nearly no excess risk of endometrial adverse effects (3 , 5) , it has been hypothesized that in the low E₂ environment of menopause, TAM can function as an estrogen agonist on the human endometrial tissue and thus may cause endometrial pathologies (6) . The hormonal dependencies of endometrial as well as breast cancers suggest that this difference may be attributed to the hormonal diversities of the pre- and postmenopausal hormonal milieu.

In breast tissue, the competitive binding of TAM to ER prevents the estrogen/ER-mediated gene transcription, DNA synthesis, and breast cancer cell growth (1) . Various studies showed that the effect of TAM on breast cancer cell lines was mediated through apoptosis (7, 8, 9, 10, 11) . Molecular mechanisms of the uterotrophic activity of TAM have not been clearly established nor its relevance to the active process of apoptosis in endometrial cells (1 , 12) . Thus, there is a need to understand the mechanisms by which TAM induces changes in uterine compartments. It is known that carcinogenesis often involves selective failure of apoptosis that prolongs the survival of cells after mutagenic DNA damage (13) . One of the main mechanisms through which oncogenes promote carcinogenesis is by inhibition of apoptosis (14 , 15) . Acquired resistance toward apoptosis is a hallmark of most cancer types (14) . Moreover, dysregulation of apoptosis has been observed in different neoplasms of the endometrium and is likely to be associated with genetic alteration, driving progression along the hyperplasia-atypiacarcinoma sequence (16) .

The present study was implemented to elucidate the cellular mechanism through which TAM exerts it stimulatory effect on postmenopausal human endometrium. In simulation of the postmenopausal hormonal environment, we maintained cell cultures in SH-devoid medium and compared these cultures to the same cells maintained in SH-containing medium. We evaluated the effect of TAM and the relevance of SH content in the medium to the effect of TAM on cultured endometrial cells, measured as the apoptotic cell population and as the levels of the main antiapoptotic protein Bcl2.

	MATERIALS AND METHODS

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Materials.
All culture media and supplements were purchased from Biological Industries (Beit Haemek, Israel).

Tissues.
We obtained human endometrial samples by curetting the uterine cavity, after the removal of the uterus, from 20 randomly assigned patients admitted for hysterectomy because of benign pathology. Detailed information including medical data, history, and indications for surgery was recorded. All endometrial tissue samples underwent pathological evaluation, and abnormal samples were excluded from the study. Institutional and Israeli Health Ministry Helsinki approvals were obtained.

Establishment of Primary Endometrial Cell Cultures.
Each endometrial sample was minced into small pieces (1–2 mm³) under aseptic conditions. The resulting pieces were incubated for 2 h in Leibovitz medium supplemented with 200 units/ml collagenase, 1000 units/ml hyaluronidase, and antibiotics at 37°C with an occasional vigorous shake. The suspension was centrifuged at 300 x g for 8 min, and after removal of the supernatant, the cellular pellet was resuspended in DMEM supplemented with 10% FCS, glutamine, and antibiotics. The cells were seeded in 25-cm² plastic culture flasks and incubated at 37°C under a humidified atmosphere. Twenty-four h later, the medium and the nonadherent cells were replaced with fresh medium.

Immunocytochemistry.
The epithelial identity of cells in culture was confirmed by immunocytochemical staining with monoclonal antibodies (Dako, Copenhagen, Denmark) against specific markers: cytokeratin for epithelial cells and vimentin for mesenchymal cells. Cells were fixated and perforated in the 6-cm² Petri dishes with 100% cold methanol and incubated with anticytokeratin antibody, respectively, with antivimentin antibody. Immunostaining was performed using the biotin-streptavidin-immunoperoxidase method using the Histostain-plus kit (Zymed Laboratories, Inc., San Francisco, CA). Visualization was achieved by the addition of 3-amino-ethylcarbazol substrate (Zymed Laboratories Inc.). All cytoplasmic red staining was considered positive.

Maintenance of Endometrial Primary Cell Cultures.
Cell cultures were grown in DMEM supplemented with 10% FCS and after 2 weeks were split into two subcultures. The subcultures were maintained 7 days either in the presence (DMEM with 10% FCS) or absence (phenol red-free DMEM and 10% charcoal stripped FCS) of SHs in culture medium.

Administration of TAM.
Twenty-four h before the experiment, cells maintained either in medium with SH or in SH-deficient medium were seeded in six-well plates (10⁵ cells/well) in a medium containing DMEM-12/HAM (1:1) supplemented with 10% FCS, 1% glutamine, and antibiotics or in phenol-red free DMEM-12/HAM (1:1) supplemented with 10% charcoal-stripped FCS. On the day of the experiment, the medium together with all nonadherent cells was removed and replaced with fresh medium. The optimal administered concentration of TAM was established by standard curve (5–25 µM) and set as the maximal nontoxic effect at 20 µM TAM (Sigma, St. Louis, MO). The cells were treated for 24 h with either 20 µM TAM or 10 nM E2 (Sigma). Ethanol was administered as a negative control. All experiments were carried out in duplicates. The suspensions were centrifuged at 300 x g for 8 min, perforated, and fixed with 70% cold methanol (-20°C for 40 min).

Analysis of Apoptotic Cell Population.
Perforated cells were incubated for 15 min at 4°C with 400 µl propidium iodide diluted in PBS (1 mg/ml), and fluorescence was analyzed by a Coulter flow cytometer (EPICS-XL; Beckman Coulter, Bristol, United Kingdom). The apoptotic cells were presented in a pre-G₁ peak. At least 10,000 events were counted in each flow cytometry (FACS) analysis.

Detection of Antiapoptotic Bcl2 Protein.
Perforated cells were incubated for 30 min at 4°C and in the dark with 10 µl of FITC-conjugated monoclonal mouse antihuman Bcl2 antibodies (Dako) and then washed and resuspended in 400 µl of PBS. Cell-associated fluorescence was analyzed by FACS. At least 10,000 events were counted in each FACS analysis.

Statistical Analysis.
Statistical analyses of the data were performed using the Wilcoxon sign rank test. P < 0.05 was considered to reflect a significant difference from the corresponding control group.

	RESULTS

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Characteristics of Endometrial Samples.
The study included 15 primary endometrial cell cultures (numbered 1–15 consistently throughout the study). Clinical and pathological features of the patients’ endometrial samples are presented in Table 1 . All patients were premenopausal women ranging in age between 38 and 50 years (mean ± SD, 45.1± 3.5). Ten of the samples were in the proliferative stage of the menstrual cycle, and the other 5 were in the secretory stage. All cell cultures were negative for vimentin, ruling out the possibility of fibroblast contamination of the culture. All primary cultures were positive for staining with anticytokeratin antibodies, thus validating the epithelial nature of the culture (results not presented). Because of the variation between endometrial tissues on the one hand and the technical limitations in establishing and maintaining primary cultures on the other, not all samples were included in all aspects of the experiment.

View larger version (23K): [in this window] [in a new window] [Download PPT slide]   Fig. 1. The modulation of apoptotic pathways by TAM in endometrial primary cultures (originating from proliferative or secretory phase respectively) in different hormonal environments. a, TAM-induced changes (compared with an ethanol-administered control) in pre-G1 cell populations in endometrial primary cultures maintained in SH-containing medium. b, TAM-induced changes (compared with ethanol-administered control) in pre-G1 cell populations in endometrial primary cultures maintained in SH-deficient medium. c, comparison of TAM-induced changes in pre-G1 cell populations in endometrial cells maintained in SH-containing medium versus SH-deficient medium.

Comparison between Changes in TAM-induced pre-G₁ Peaks in Endometrial Cells Maintained in SH-containing Environments versus SH-deficient Environments.
Ten samples were evaluated in both media (with or without SHs; Fig. 1 c). In four of them, the pre-G₁ population was medium dependent, whereas the SH content of the medium did not influence the other six cultures. All three (100%) cultures originating from secretory endometrium responded in the same fashion, regardless of the contents of the medium, whereas in cultures originating from proliferative endometrium, three of seven (42%) were not affected by steroidal content, and four of seven (58%) were affected.

Comparison between Responses to TAM versus E₂, Both in Endometrial Cells Maintained in SH-containing Environments and SH-deficient Environments.
E₂ was administered to five endometrial cultures maintained in SHcontaining medium and to five cell cultures maintained in SH-deficient medium. The apoptotic response, measured as the pre-G₁ peak, was assayed. All endometrial cell cultures (10 of 10), regardless of the menstrual cycle phase, responded to TAM and E₂ in the same manner. We observed an increase in the pre-G₁ peak in both TAM- and E₂-treated cultures maintained in medium containing SHs and a decrease in the pre-G₁ population in 80% of cultures maintained in a SH-deficient environment (Fig. 2) .

View larger version (34K): [in this window] [in a new window] [Download PPT slide]   Fig. 2. Comparison of endometrial cells responses (measured as the pre-G1 peaks) to treatment with TAM versus E2 treatment.

	DISCUSSION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

Our results demonstrate that administration of TAM to primary endometrial cell cultures modulates apoptotic pathways. A significant (P = 0.03) proapoptotic effect of TAM was detected in the majority of cell cultures grown in a steroid-containing medium. This effect was not dependent on the menstrual phase of the originating endometrial samples. These results are consistent with the clinical observations in premenopausal TAM-treated breast cancer patients, in which endometrial pathologies are uncommon (3 , 5) . It was assumed that menstrual shedding, by evacuation of the uterine cavity of the possibly affected cells, eliminates the risk of endometrial pathologies. Our results suggest that TAM treatment activates apoptotic pathways in the endometrium of premenopausal women, and therefore, the lack of carcinogenic effect in hormonally active endometrium is possibly attributable to an active anticancerous process and not the result of menstrual shedding alone. The possibility that apoptosis serves as a barrier to cancer was first raised in 1972 (17) and was further supported by numerous studies (14) . The clinical observation that TAM treatment might reverse endometrial hyperplasia in premenopausal women (18) further supports our assumption, that in the presence of high endogenous estrogen levels, TAM acts in a protective manner.

Two opposing trends (proapoptotic and antiapoptotic) were observed in cells maintained in a steroid-deficient medium. Of the examined samples, 46% demonstrated a significant antiapoptotic response (P = 0.03). This effect is consistent with the clinically known, estrogenic-like agonistic effect of TAM in the low estrogenic environment of menopause. This effect may explain why a relatively high percentage (25–30%) of postmenopausal TAM-treated patients develop different endometrial pathologies, including endometrial carcinoma (4 , 5) .

Opposing effects of TAM on the apoptotic cell population of the primary cell cultures were observed as a consequence of different media. Our results suggest that TAM modulates the apoptotic pathways in endometrial cells, but the progression toward apoptosis or carcinogenesis is influenced by the hormonal environment of the cell. The significance of the hormonal environment is further supported by studies carried out on cell lines (19 , 20) . In a recent article (21) , immunohistochemical studies of the Ki67 index also indicate that TAM exerts an antiestrogenic effect on the endometrium in the presence of endogenous estrogen secretion and an estrogenic effect in the absence of estrogen secretion. This mechanism is further supported by Cross et al. (22) , who describes the occurrence of complex atypical hyperplasia in an ovariectomized premenopausal breast cancer patient undergoing TAM treatment. A similar modulation of the effect of TAM by the hormonal milieu was described previously in bone tissue (23) .

We analyzed the effect of TAM on apoptosis of the endometrial cultures according to the menstrual cycle from which they originated. Secretory endometrium was insensitive to changes in the SH content in the medium. Proliferative endometrium was most often affected by the hormonal content. A possible explanation is preconditioning of the endometrium removed at the secretory phase, thus rendering it unresponsive to the SH content.

Two opposing trends in Bcl2 expression were observed, regardless of the steroidal content of the medium and of the menstrual phase of the originating endometrium. Moreover, a lack of consistent association is demonstrated between Bcl2 expression and the anti- or proapoptotic effect of TAM on endometrial cells. The association between overexpression of Bcl2 and endometrial carcinogenesis has not been demonstrated yet. Contradictory findings have been described with regard to Bcl2 expression in neoplastic endometrial tissue (24, 25, 26, 27) . Thus, the association between Bcl2 expression and apoptosis in normal and neoplastic endometrial tissue is not conclusive (27, 28, 29) . Although Bcl2 is highly expressed in normal proliferative and hyperplastic endometrium, it is significantly down-regulated in atypical hyperplasia and adenocarcinoma. It was suggested that the role of Bcl2 in preventing cell death is bypassed in the progression of atypical hyperplasia to carcinoma by other factors impeding apoptosis (24 , 25) . Marked reduction in Bcl-2 protein levels, although rendering cells more prone to apoptosis, are by themselves often insufficient to cause cell death (30) . The Bcl2:Bax ratio is considered to be a more important checkpoint in the modulation of the apoptotic process than the absolute level of either Bcl2 or Bax (31) ; therefore, the expression of Bax should be studied and might shed light on this dilemma.

TAM has been shown to have an estrogen-like agonistic effect on the endometrium in animal and human studies (32 , 33) . Our results show a complete correlation between TAM and E₂ responses in all cell cultures, regardless of the menstrual phase of tested endometrium or steroid content in the medium. The results obtained in the steroid-free medium support the mechanism of an estrogen-like effect of TAM and the hypothesis that TAM affects the endometrial cell through the ER pathway, similar to that of estrogen itself. Different studies have shown that ER recognizes a similar estrogen response element with TAM, as with estrogen itself, and that TAM and E₂ induces similar proto-oncogenes (1 , 34) . A recent study provides further documentation that the uterotrophic effect of TAM on postmenopausal endometrium may be attributable to overexpression of both ERs and progesterone receptors (35) . However, this approach cannot explain the results seen in the steroid-containing medium. Because E₂ is known to have an antiapoptotic effect (36 , 37) , we would expect that the addition of E₂ to the medium would further reduce the pre-G₁ population. But an opposite effect was observed in our experiments.

Unraveling the mechanistic aspects of the effect of TAM on the endometrium may have applicable consequences as well. Our model may serve as an ex vivo prognostic assay for the risk of endometrial carcinoma development after TAM treatment in postmenopausal women. Moreover, because TAM is used as a chemopreventive agent in healthy patients, there is a clear need to elucidate the mechanism of the action of TAM in the reproductive tract. A better understanding will enable prediction of which groups of patients are more susceptible to develop endometrial pathologies.

	ACKNOWLEDGMENTS

 
We thank Dr. H. Loberboum-Galski (Hebrew University, Jerusalem, Israel) for help and H. Shapira (Meir Hospital, Tel Aviv, Israel) for assistance with the FACS. The assistance of D. Rosenzal and Dr. Y. Bomstein (immunocytochemistry) is appreciated.

	FOOTNOTES

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ To whom requests for reprints should be addressed, at Oncogenetics Laboratory, Sapir Medical Center, Meir Hospital, Kfar Sava 44281, Israel. Phone: 972-9-7472466; Fax: 972-9-7472369; E-mail: DruckerHey{at}hotmail.com

² The abbreviations used are: TAM, tamoxifen; ER, estrogen receptor; E₂, estradiol; SH, steroid hormone; FACS, fluorescence-activated cell sorter.

Received 5/31/00; revised 10/13/00; accepted 11/ 2/00.

	REFERENCES

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 

1. MacGregor J. I., Jordan C. , Basic guide to the mechanisms of antiestrogens.. Pharmacol. Rev., 50: 151-196, 1998.[Abstract/Free Full Text]
2. Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet, 339: 1–15, 71–85, 1992.
3. Fisher B., Constantino J. P., Wickerman D. L., Redmond C. K., Kavanah M., Cronin W. M., Vogel V., Robidoux A., Dimitrov N., Atkins J., Daly M., Wieand S., Tan-Chiu E., Ford L., Wolkman N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.. J. Natl. Cancer Inst., 90: 1371-1388, 1998.[Abstract/Free Full Text]
4. Cohen I., Beyth Y., Tepper R. The role of ultrasound in the detection of endometrial pathologies in asymptomatic postmenopausal breast cancer patients with tamoxifen treatment.. Obstet Gynecol. Surv., 53: 429-438, 1998.[CrossRef][Medline]
5. Cheng W-F., Lin H-H., Tong P-I., Huang S-C. Comparison of endometrial changes among symptomatic tamoxifen-treated and non-treated premenopausal and postmenopausal breast cancer patients.. Gynecol. Oncol., 66: 233-237, 1997.[CrossRef][Medline]
6. Gusberg S. B. Tamoxifen for breast cancer: associated endometrial cancer.. Cancer (Phila.), 65: 1463-1464, 1990.[CrossRef][Medline]
7. Ellis P. A., Saccani-Jotti G., Clarke R., Johnston S. R., Anderson E., Howell A., A’Hern R., Salter J., Detre S., Nicholson R., Robertson J., Smith I. E., Dowsett M. Induction of apoptosis by tamoxifen and ICI 182,780 in primary breast cancer.. Int. J. Cancer, 72: 608-613, 1997.[CrossRef][Medline]
8. Budtz P. , E.. Role of proliferation and apoptosis in net growth rate of human breast cancer cells (MCF-7) treated with oestrogen and/or tamoxifen. Cell Prolif., 32: 289-302, 1999.
9. Cameron D. A., Keen J. C., Dixon J. M., Bellamy C., Handy A., Miller W. R. Effective tamoxifen therapy of breast cancer involves antiproliferative and pro-apoptotic changes.. Eur. J. Cancer, 36: 845-851, 2000.
10. Zhang G. J., Kimijima I., Onda M., Kanno M., Sato H., Watanabe T., Tsuchiya A., Abe R., Takenoshita S. Tamoxifen induced apoptosis in breast cancer cells related to down-regulation of bcl-2, but not bax and bcl-X_L, without alteration of p53 protein levels.. Clin. Cancer Res., 5: 2971-2977, 1999.[Abstract/Free Full Text]
11. Swiatecka J., Dzieciol J., Anchim T., Dabrowska M., Pietruczuk, Wolczynski S. Influence of estrogen, antiestrogen and UV-light on the balance between proliferation and apoptosis in MCF-7 adenocarcinoma cells culture.. Neoplasma, 47: 15-24, 2000.[Medline]
12. Friedl, A., and Jordan, V. C. What do we know and what don’t we know about tamoxifen in the human uterus. Breast Cancer Res. Treat., 31: 27–39, 1994 .
13. Thompson C. B. , Apoptosis in the pathogenesis and treatment of the diseases.. Science (Washington DC), 264: 1456-1462, 1995.
14. Douglas H., Weinberg R. A. The Hallmarks of Cancer.. Cell, 100: 57-70, 2000.[CrossRef][Medline]
15. Agnatis N. J., Goussia A. C. Apoptosis and cancer.. Bull. Acad. Natl. Med., 183: 277-286, 1999.[Medline]
16. Arends M. J. Apoptosis in the endometrium.. Histopathology, 35: 174-178, 1999.[CrossRef][Medline]
17. Kerr J. F., Willie A. H., Currie A. R. Apoptosis: abasic biological phenomenon with wide-ranging implications in tissue kinetics.. Br. J. Cancer, 26: 236-257, 1972.
18. El-Tomi N. F., Hassan S., Youssef F., Labib N., Ali N., Hathout H. The effect of tamoxifen on endometrial hyperplasia.. J. Kuwait Med. Assoc., 19: 175-181, 1985.
19. Anzai Y., Holinka C. F., Kuramoto H., Gurpide E. Stimulatory Effects of 4-hydroxytamoxifen on proliferation of human endometrial adenocarcinoma cells (Ishikawa line).. Cancer Res., 49: 2362-2365, 1989.[Abstract/Free Full Text]
20. Terakawa N., Shimizu I., Ikegami H., Tanizawa O., Matsumoto K. 4-Hydroxytamoxifen binds to estrogen receptors and inhibits the growth of human endometrial cells in vitro.. Cancer (Phila.), 61: 1312-1315, 1988.[CrossRef][Medline]
21. Hachisuga T., Hideshima T., Kawarabayashi T., Eguchi F., Emoto M., Shirakusa T. Expression of steroid receptors, Ki-67, and epidermal growth factor receptor in tamoxifen-treated endometrium.. Int. J. Gynecol. Pathol., 18: 297-303, 1999.[Medline]
22. Cross S. S., Ismail S. M. Endometrial hyperplasia in an oophorectomized woman receiving tamoxifen therapy.. Case report. Br. J. Obstet. Gynecol., 97: 190-192, 1990.
23. Mitlak B. H., Cohen F. J. Selective estrogen receptor modulators.. A Look Ahead. Drugs, 57: 653-663, 1999.[CrossRef][Medline]
24. Chhieng D. C., Ross J. S., Ambros R. A. bcl-2 expression and the development of endometrial carcinoma.. Mod. Pathol., 9: 402-406, 1996.[Medline]
25. Henderson G. S., Brown K. A., Perkins S. L., Abbott T. M., Clayton F. bcl-2 is down regulated in atypical endometrial hyperplasia and adenocarcinoma.. Mod. Pathol., 9: 430-438, 1996.[Medline]
26. Sakuragi N., Ohkouchi T., Hareyama H., Ikeda K., Watary H., Fujimoto T., Kuwabara M., Yamamato R., Sagawa T., Fujino T., Fujimoto S. Bcl-2 expression and prognosis of patients with endometrial carcinoma.. Int. J. Cancer, 79: 153-158, 1998.[CrossRef][Medline]
27. Watanabe H., Kanzaki H., Narukawa S., Inoue T., Katsuragawa H., Kaneko Y., Mori T. Bcl-2 and Fas expression in eutopic and ectopic human endometrium during the menstrual cycle in relation to endometrial cell apoptosis.. Am. J. Obstet. Gynecol., 176: 360-368, 1997.[CrossRef][Medline]
28. Otsuki Y., Misaki O., Sugimoto O., Ito Y., Tsujimoto Y., Akao Y. Cyclic bcl-2 gene expression in human uterine endometrium during menstrual cycle.. Lancet, 2: 28-29, 1994.[CrossRef]
29. Ioffe O. B., Papadimitriou J. C., Drachenberg C. B. Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium.. Hum. Pathol., 29: 1150-1159, 1998.[CrossRef][Medline]
30. Reed J. C. Bcl-2 and the regulation of programmed cell death.. J. Cell Biol., 124: 1-6, 1994.[Free Full Text]
31. Sedlak T. W., Olltvai Z. N., Yang E., Boise L. H., Thompson C. B., Korsmeyer S. J. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax.. Proc. Natl. Acad. Sci. USA, 92: 7834-7838, 1995.[Abstract/Free Full Text]
32. Satyaswaroop P. G., Zaino R. J., Mortel R. Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice.. Cancer Res., 44: 4006-4010, 1984.[Abstract/Free Full Text]
33. Gorodeski G. I., Beery R., Lunenfeld B., Geier A. Tamoxifen increases plasma estrogen-binding equivalents and has an estradiol agonistic effect on histologically normal premenopausal and postmenopausal endometrium.. Fertil. Steril., 57: 320-325, 1992.[Medline]
34. Nephew K. P., Polek T. C., Khan S. A. Tamoxifen induced proto-oncogene expression persists in uterine endometrial epithelium.. Endocrinology, 137: 219-224, 1996.[Abstract]
35. Elkas J., Armstrong A., Pohl J., Cuttitta F., Martinez A., Gray K. Modulation of endometrial steroid receptors and grow regulatory genes by tamoxifen.. Obstet. Gynecol., 95: 697-703, 2000.[CrossRef][Medline]
36. Wang T. T., Phang J. M. Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7.. Cancer Res., 55: 2487-2489, 1995.[Abstract/Free Full Text]
37. Kyprinou N., English H. F., Davidson N. E., Isaacs J. T. Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation.. Cancer Res., 51: 162-166, 1991.[Abstract/Free Full Text]

This article has been cited by other articles:

				J.-H. Yang, M.-Y. Wu, C.-D. Chen, M.-J. Chen, Y.-S. Yang, and H.-N. Ho Altered apoptosis and proliferation in endometrial stromal cells of women with adenomyosis Hum. Reprod., April 1, 2007; 22(4): 945 - 952. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stackievicz, R. Articles by Cohen, I. Search for Related Content PubMed PubMed Citation Articles by Stackievicz, R. Articles by Cohen, I.